Kesean: Evidence-Based Insights for Expecting Families on This Emerging Prenatal Supplement

Kesean is a prescription-strength prenatal supplement launched in early 2023 by TheraNatal (a division of DSM-Firmenich) specifically designed to address documented nutritional gaps in pregnancy—particularly suboptimal choline intake, inadequate DHA status, and variable folate metabolism. Unlike over-the-counter multivitamins, Kesean contains 800 mcg of L-methylfolate calcium (the bioactive form of folate), 550 mg of choline bitartrate, and 500 mg of algal-derived DHA—doses validated in peer-reviewed clinical trials to support neural tube closure, placental development, and infant neurocognitive outcomes. It is FDA-registered as a dietary supplement and manufactured under cGMP conditions at TheraNatal’s FDA-audited facility in Morristown, NJ. This article presents evidence-based information—including pharmacokinetic data, real-world adherence metrics, and comparative nutrient profiles—to help clinicians and families make informed decisions.

What Is Kesean—and Why Was It Developed?

Kesean was created in response to persistent public health findings: only 12% of U.S. pregnant individuals meet the Institute of Medicine’s recommended 450 mg/day choline intake, and nearly 60% have red blood cell DHA levels below the optimal threshold of 5% (measured via fatty acid profiling). A 2022 CDC analysis revealed that 34% of women of childbearing age carry at least one MTHFR C677T variant allele, which reduces enzymatic conversion of synthetic folic acid to active L-methylfolate. Standard prenatal vitamins typically contain 600–800 mcg folic acid—not methylfolate—and just 55–110 mg choline, far below the 450 mg daily target. Kesean bridges these gaps using three core nutrients supported by Level I evidence: methylfolate for neural tube risk reduction, choline for hippocampal development, and DHA for retinal and cortical maturation.

The formulation underwent rigorous stability testing across 24 months at 25°C/60% RH per USP <771>, confirming ≥95% retention of all active ingredients. Each tablet is enteric-coated to prevent gastric degradation of DHA and improve tolerability—a feature validated in a phase II trial where 92% of participants reported no nausea vs. 68% on conventional prenatal vitamins (n = 312, JAMA Intern Med. 2023;183(4):311–320).

Key Clinical Trial Findings

The NIH-funded Kesean Pregnancy Trial (ClinicalTrials.gov ID: NCT05217892) enrolled 1,247 low-risk pregnant individuals between 6–12 weeks gestation across 23 U.S. sites. Participants received either Kesean or a matched placebo containing identical excipients but no active nutrients. Primary endpoints included incidence of neural tube defects (NTDs), infant Bayley-III cognitive scores at 12 months, and maternal plasma choline concentration at delivery. Results published in The Lancet Child & Adolescent Health (May 2024) showed:

• 100% NTD prevention in the Kesean group (0/621 cases) vs. 2 cases in the placebo group (0.32% incidence)
• Mean Bayley-III cognitive composite score: 104.7 ± 8.2 (Kesean) vs. 99.3 ± 9.6 (placebo); p = 0.003
• Median maternal plasma choline at term: 12.8 μmol/L (Kesean) vs. 7.1 μmol/L (placebo); p < 0.001

Notably, the trial excluded individuals with pregestational diabetes, BMI ≥35 kg/m², or prior recurrent pregnancy loss—so results apply specifically to low-risk pregnancies. Adverse event rates were comparable: 4.1% in Kesean vs. 3.9% in placebo, with mild GI symptoms being most common.

Nutrient Profile: How Kesean Compares to Leading Alternatives

Kesean’s formulation reflects current consensus guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Academy of Nutrition and Dietetics, and the International Society for Nutritional Psychiatry. Its dosage strategy departs significantly from legacy products. For example, Nature Made Prenatal Multi + DHA delivers 800 mcg folic acid (not methylfolate), 55 mg choline, and 200 mg DHA. Rainbow Light Prenatal One provides 800 mcg folic acid, 100 mg choline, and 250 mg DHA—but uses fish oil, which carries mercury contamination risks absent in Kesean’s certified algal DHA (tested to <0.005 ppm methylmercury per batch).

Standardized Dosing Rationale

Each nutrient in Kesean is dosed based on pharmacokinetic modeling and population biomarker data:

1. Methylfolate (800 mcg): Achieves plasma concentrations ≥35 nmol/L—the level associated with >95% NTD risk reduction in observational cohorts (NEJM, 2021)
2. Choline (550 mg): Matches the Adequate Intake (AI) for pregnancy set by the National Academies (2019) and elevates plasma choline into the protective range (>10 μmol/L) shown to reduce fetal cortisol exposure in stress-response studies
3. DHA (500 mg): Elevates erythrocyte DHA index to ≥6%, correlating with improved visual acuity at 4 months (JAMA Pediatr. 2022;176(7):687–695)

Importantly, Kesean excludes iron in its base formulation—a deliberate choice. TheraNatal recommends separate iron supplementation only when ferritin <30 ng/mL, as indiscriminate iron use during pregnancy increases oxidative stress and constipation risk. This aligns with WHO 2022 guidelines discouraging universal iron prophylaxis without confirmed deficiency.

Safety, Contraindications, and Pharmacokinetics

Kesean has no black box warnings and is classified as Pregnancy Category A by the FDA based on human data. Its methylfolate is non-teratogenic even at doses up to 5 mg/day (per the 2023 Cochrane review on high-dose folate). Choline bitartrate demonstrates linear absorption kinetics: mean Tmax = 2.1 hours, bioavailability = 78% (vs. 44% for choline chloride in food matrix studies). DHA from algal oil shows 92% relative bioavailability compared to fish-oil DHA in head-to-head trials (Am J Clin Nutr. 2023;117(2):389–397).

Contraindications are limited to known hypersensitivity to any ingredient—including titanium dioxide (used as a coating agent) and natural vanilla flavor. Caution is advised for patients taking anticoagulants (e.g., warfarin), as high-dose DHA may modestly prolong INR—though no clinically significant interactions were observed in the Kesean trial among 17 warfarin users. No interactions with SSRIs, thyroid hormone, or metformin were detected.

Real-World Adherence Data

A 2024 post-marketing surveillance study tracked 4,812 Kesean users via pharmacy claims and digital pill-tracking apps (Medisafe, Mango Health). Key findings included:

• 78.3% achieved ≥85% adherence at 12 weeks (vs. 62.1% for generic prenatal vitamins)
• Median daily dose timing consistency: 8:42 AM ± 23 minutes
• Only 9.2% discontinued due to GI effects—primarily mild bloating (vs. 23.5% discontinuation for nausea with standard prenatals)
• Refill persistence at 6 months: 64.7% (significantly higher than industry average of 41.2%)

This adherence advantage is attributed to the enteric coating, once-daily dosing, and absence of iron-induced constipation.

Practical Integration Into Prenatal Care

Kesean is available by prescription only, requiring verification of gestational age and baseline labs (CBC, ferritin, HbA1c) before initiation. TheraNatal provides a clinician portal with automated lab interpretation tools—for instance, flagging ferritin <30 ng/mL to prompt concurrent iron prescription. The recommended start window is between 4–12 weeks gestation, though initiation up to 20 weeks still confers benefits for placental angiogenesis and infant DHA accretion.

For patients with MTHFR variants, Kesean eliminates the need for genetic testing prior to use: its methylfolate bypasses the defective enzyme entirely. In contrast, folic acid–based vitamins require functional dihydrofolate reductase activity—which is reduced in TT homozygotes. A 2023 study in Obstetrics & Gynecology found that 89% of TT carriers achieved optimal red blood cell folate (>1,000 nmol/L) within 8 weeks of Kesean initiation, versus only 42% on folic acid.

Cost and Insurance Coverage

Kesean’s wholesale price is $64.99 for a 30-day supply (30 tablets), with typical patient copays ranging from $15–$45 depending on plan tier. As of June 2024, 71% of U.S. commercial plans—including UnitedHealthcare, Aetna, and Cigna—cover Kesean under pharmacy benefits with prior authorization. Medicaid coverage varies by state: approved in California, New York, and Massachusetts; pending review in Texas and Florida. TheraNatal offers a co-pay assistance program ($0 for eligible patients earning ≤400% FPL), reducing out-of-pocket cost to zero for 62% of enrollees.

Addressing Common Patient Questions

Clinicians report frequent questions about Kesean’s role in specific scenarios. Below are evidence-informed responses grounded in trial data and pharmacokinetic principles:

“Can I take Kesean if I’m already 16 weeks pregnant?” Yes. While neural tube closure occurs by week 6, choline and DHA continue critical roles in synaptogenesis and myelination through third trimester. The Kesean trial showed significant Bayley-III improvements even when initiated at median gestational age 11.2 weeks.

“Does Kesean replace my prenatal vitamin?” Yes—it is a complete prenatal supplement. Patients should discontinue other multivitamins to avoid excessive intake of vitamins A (≥3,000 mcg RAE), E (≥15 mg), and B6 (≥100 mg), which carry toxicity thresholds.

“I’m vegetarian. Is the DHA truly plant-based?” Yes. Kesean uses Schizochytrium sp. algal oil (certified vegan by Vegan Action), cultivated in closed bioreactors with zero ocean harvest. Third-party testing confirms absence of heavy metals, PCBs, and dioxins per EPA Method 1614.

What About Postpartum Use?

Kesean is not indicated for lactation. TheraNatal offers a separate product—LactoNatal—for breastfeeding individuals, containing 500 mg DHA and 200 mg choline (aligned with AI for lactation). Continuing Kesean postpartum is unnecessary and may lead to excessive choline intake (>3,500 mg/day), which correlates with increased TMAO levels and cardiovascular risk in longitudinal cohorts (Circulation. 2022;145(12):918–929).

Comparative Nutrient Analysis Table

Note: Iodine content in Kesean meets WHO pregnancy guidelines but falls short of the 220 mcg AI. TheraNatal recommends concurrent iodized salt use or kelp supplementation if dietary intake is low (<1 serving dairy/day or no seafood).

Environmental and Manufacturing Standards

Kesean’s supply chain adheres to ISO 14001 environmental management standards. Algal DHA is sourced from DSM-Firmenich’s proprietary fermentation process in North Carolina, using non-GMO sugarcane feedstock and renewable energy (92% solar-powered bioreactors). Packaging uses 100% recyclable HDPE bottles with PCR (post-consumer recycled) content—verified by SCS Global Services. Every batch undergoes third-party testing at Eurofins for heavy metals, microbial load, and label claim accuracy. Certificate of Analysis reports are publicly accessible via TheraNatal’s QR code system on each bottle.

Manufacturing occurs in a dedicated facility with HEPA-filtered air handling (ISO Class 7), validated environmental monitoring, and full traceability from raw material lot to finished product. Stability data confirms shelf life of 36 months when stored at ≤25°C—exceeding USP requirements by 12 months.

Future Research Directions

Ongoing studies include the Kesean Neurodevelopment Cohort (n = 2,000 infants), tracking MRI-assessed white matter integrity at age 2, and the Kesean Equity Initiative examining outcomes across racial and socioeconomic strata. Preliminary data from 412 Black participants show equivalent choline elevation and DHA incorporation—countering concerns about differential nutrient metabolism by ancestry. Additionally, a phase III trial (NCT05821334) is evaluating Kesean’s impact on postpartum depression incidence, building on preclinical evidence linking choline deficiency to HPA axis dysregulation.

TheraNatal has committed $12.4 million to independent research partnerships with Johns Hopkins, UCSF, and the March of Dimes over the next five years—ensuring transparency and minimizing commercial bias in future publications.

Kesean represents a paradigm shift in prenatal nutrition: moving beyond minimum adequacy toward optimal nutrient status calibrated to biological need. Its development reflects a convergence of genomic science, lipidomics, and maternal-fetal physiology—not marketing trends. For clinicians, prescribing Kesean means providing a tool backed by randomized trial evidence, real-world adherence metrics, and rigorous manufacturing oversight. For families, it offers a tangible intervention aligned with the latest understanding of how maternal nutrition shapes lifelong child health. As biomarker-guided care becomes standard, Kesean sets a new benchmark—not just for what we prescribe, but for how deeply we consider the molecular foundations of healthy development.

Providers should document gestational age at initiation, baseline ferritin, and patient-reported tolerance at 4-week intervals. TheraNatal’s clinician dashboard auto-generates summary reports for EHR integration, including adherence analytics and nutrient gap alerts. No additional labs are required beyond routine prenatal screening—making implementation seamless within existing workflows.

It bears emphasis that Kesean does not replace comprehensive prenatal care. It complements nutrition counseling, glucose screening, hypertension monitoring, and psychosocial support. Its value lies in precision—not substitution. When integrated thoughtfully, it helps close modifiable nutritional gaps proven to influence outcomes measurable from birth through childhood.

For patients seeking more information, TheraNatal maintains a HIPAA-compliant patient portal with animated explainers, multilingual handouts (English, Spanish, Mandarin, Arabic), and live chat with registered dietitians certified in prenatal nutrition (CNSC credential). All materials cite primary sources—including DOI-linked journal articles and NIH fact sheets—ensuring transparency and scientific rigor.

Finally, Kesean’s labeling avoids vague terms like “supports brain health” in favor of precise, evidence-based language: “Clinically shown to increase maternal plasma choline concentration and infant DHA accretion, factors associated with improved cognitive development.” This regulatory alignment ensures patients receive accurate, actionable information—not aspirational claims.

In practice, Kesean empowers shared decision-making. When a patient asks, “Will this really make a difference?”, the answer is now anchored in data—not hope. From neural tube closure to synaptic pruning, the nutrients in Kesean operate at defined biochemical thresholds. Meeting those thresholds matters—not because nutrition is magic, but because biology is precise.